A Phase II Randomized Clinical Trial of Panitumumab plus Gemcitabine and Oxaliplatin (GEMOX) versus GEMOX alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma.

Trial Profile

A Phase II Randomized Clinical Trial of Panitumumab plus Gemcitabine and Oxaliplatin (GEMOX) versus GEMOX alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Panitumumab (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Biliary cancer
  • Focus Therapeutic Use
  • Acronyms Vecti-BIL
  • Most Recent Events

    • 05 Nov 2015 Results published in the Cancer
    • 27 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 12 Nov 2013 Planned End Date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top